Keturah Completes Infrastructure Works for ‘The Ritz-Carlton Residences, Dubai, Creekside,’ Starts Construction
Keturah, the revolutionary global luxury wellbeing real estate and hospitality concept has announced key construction milestones with the completion of shoring, piling, excavation and infrastructure works at The Ritz-Carlton Residences, Dubai, Creekside. The project’s main contractor, CECEP Techand Middle East, has commenced construction on the AED 2.8 billion development, which is scheduled for completion by Q4 2027.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114351975/en/
The Ritz-Carlton Residences, Dubai, Creekside at the Keturah Resort (Photo: AETOSWire)
Located within Keturah Resort, the first fully wellness-certified resort in the MENA region, The Ritz-Carlton Residences, Dubai, Creekside comprises 200 residences across seven buildings and 12 mansions, each featuring exclusive yacht berthing for residents. Homeowners will benefit from an impressive range of world-class facilities, including a wellness center, a Clubhouse, complete with a private members-only club, a ladies’ club, a kids’ club, fine dining and Michelin-star restaurants, a 550-metre promenade, sustainable and organic-focused retail spaces, 24/7 private parking with valet, and a gated community with unique views of the wildlife sanctuary and Burj Khalifa.
In his comments, Mo Moghrabi, Chief Development Officer at Keturah, said, “We are pleased with these construction milestones, and the start of work on the project by CECEP. The project reflects Keturah’s efforts to provide an immersive wellness-luxury lifestyle across Dubai, adopting a comprehensive approach and offering top-notch amenities within The Residences to meet the global appeal on premium properties across the emirate.”
Jaidev Menezes, Regional Vice President - Mixed-Use Development, EMEA at Marriott International said, “We are excited at this significant milestone bringing us a step closer to offering future homeowners of The Ritz-Carlton Residences, Dubai, Creekside, an exceptional lifestyle marked by the legendary anticipatory service of The Ritz-Carlton brand.”
Each residence adheres to the WELL Certification Standards and is complemented by ultra-high-end leisure areas as well as exclusive spa and wellness facilities, all of which meet the WELL Health-Safety Rating. The project is located on Dubai Creek, facing Dubai’s wildlife sanctuary in Ras Al Khor, providing convenient access to Dubai Downtown.
For more information, explore www.theresidencescreeksidedubai.com
Legal Disclaimer
The Ritz-Carlton Residences, Dubai, Creekside, are not owned, developed, or sold by The Ritz-Carlton Hotel Company, LLC or its affiliates (“Ritz-Carlton”). MAG of Life FZ-LLC uses The Ritz-Carlton marks under a license from Ritz-Carlton, which has not confirmed the accuracy of any of the statements or representations made herein.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241114351975/en/
Contacts
Cicero & Bernay
Khaled Abu Hishme
khaled@cbpr.me
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Cell and Gene Therapy Trials: Driving Innovation in Oncology and Beyond14.11.2024 14:05:00 CET | Press Release
Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114441933/en/ Key Highlights from the Report: Global Clinical Trial Expansion: Over 1,500 drug candidates in development across phases 0 to III. CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers. The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials). Oncology Focus: CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and
REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202414.11.2024 13:52:00 CET | Press Release
Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2024. The Group's consolidated turnover in the first nine months of the year reached €1,666.9 million, an increase of 7.7% compared to €1,548.0 million recorded on 30 September 2023. The indicators for the period are positive. Consolidated EBITDA was €275.5 million, equal to 16.5% of the consolidated revenues. As of September 2023 EBITDA was €235.8 million. EBIT, from January to September, reached €224.2 million, equal to 13.4% of the consolidated revenues. The corresponding 2003 figure was €187.7 million. Pre-tax profit, from January to September 2024, was €216.0 million, equal to 13.0% of the revenues. As of September 2023 pre-tax profit stood at €170.3 million. For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €552.6 million compared to €509.1 million of the third quarter 2023. EBITDA, from July to September 2024, was equa
Experian Named to World’s Best Workplaces™ 2024 by Fortune and Great Place to Work ®14.11.2024 13:22:00 CET | Press Release
Experian today announced it was named one of the World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®, which recognises a select 25 global companies that are building the best workplace cultures in the world. The honour highlights Experian’s people-first workplace culture that promotes inclusivity, fosters collaboration and innovation, and prioritises team member well-being, personal growth, and advancement. In its 14th year of producing this prestigious international list, Great Place To Work® surveyed 6.2 million employees worldwide on key factors that create great workplaces and analysed company workplace programmes that impact 18 million employees globally. Organisations were assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. “This is a great recognition,” said Brian Cassin, Chief Executive Officer of Experian. “It’s a testament to the hard work, dedication, and creativity that o
Rogers Investment Advisors leads FSR Angel 1 LPS investment in XELA Robotics Expansion to Drive Global Ambitions14.11.2024 13:00:00 CET | Press Release
XELA Robotics Co., Ltd., (“XELA”), a pioneer in tactile sensing and advanced tactile AI-driven robotic solutions, today announced a significant 7-digit (USD) investment by FSR Angel 1 LPS (“FSR”), managed by Rogers Investment Advisors K.K.(“RIA”). The investment reinforces XELA’s vision to expand its global footprint while maintaining its position as a leader in tactile AI technology. The founding team will remain the majority shareholders of XELA, a company spun off from Waseda University, one of Japan’s most prestigious academic institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114649471/en/ XELA Robotics CEO Alexander Schmitz with key investors from FSR Angel 1 LPS and Rogers Investment Advisors K.K., marking a pivotal step in our mission to expand globally and lead in AI-driven tactile sensing. (Graphic: Business Wire) XELA’s disruptive AI technology integrates tactile sensors to open new horizons for indus
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer14.11.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/ (Graphic: Business Wire) “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing a critical role and unifying the global community in the fight against cancer. Our focus is to not only bring innovative medicines to as many people as possible, but also to identify and address the challeng
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom